Angiogenesis is a hallmark of cancer and is required for tumor growth and progression.
Antiangiogenic therapy has been revolutionarily developing and was approved for the …

Recent studies have established that tumors can reprogram the pathways involved in
nutrient uptake and metabolism to withstand the altered biosynthetic, bioenergetics and …

Background Crosstalk between neoplastic and stromal cells fosters prostate cancer (PCa)
progression and dissemination. Insight in cell-to-cell communication networks provides new …

ATP and its ultimate degradation product adenosine are potent extracellular signalling
molecules that elicit a variety of pathophysiological functions in the kidney through the …

Purpose: Resistance to antiangiogenic tyrosine kinase inhibitors such as sunitinib is an
important clinical problem, but its underlying mechanisms are largely unknown. We …

Renal cell carcinoma (RCC) is an immunogenic and proangiogenic cancer, and
antiangiogenic therapy is the current mainstay of treatment. Patients with RCC develop …

Lysophosphatidic acid (LPA) is a ubiquitous lysophospholipid and one of the main
membrane‐derived lipid signaling molecules. LPA acts as an autocrine/paracrine …

Autotaxin is a secreted enzyme that produces most of the extracellular lysophosphatidate
from lysophosphatidylcholine, the most abundant phospholipid in blood plasma …

Lysophosphatidic acid (LPA) is a bioactive lipid mediator primarily derived from membrane
phospholipids. LPA initiates cellular effects upon binding to a family of G protein-coupled …

Autotaxin (ATX) is a member of the nucleotide pyrophosphatase/phosphodiesterase family
of ectoenzymes that hydrolyzes phosphodiester bonds of various nucleotides. It possesses …